Total Payments
$62,689
2024 Payments
$268.82
Companies
22
Transactions
88
Payment Breakdown by Category
Consulting$39,239 (62.6%)
Other$15,540 (24.8%)
Travel$3,955 (6.3%)
Food & Beverage$2,165 (3.5%)
Research$1,750 (2.8%)
Education$40.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $39,239 | 11 | 62.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,010 | 9 | 12.8% |
| Honoraria | $5,415 | 8 | 8.6% |
| Travel and Lodging | $3,955 | 13 | 6.3% |
| Food and Beverage | $2,165 | 44 | 3.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,115 | 1 | 3.4% |
| Unspecified | $1,750 | 1 | 2.8% |
| Education | $40.00 | 1 | 0.1% |
Payments by Type
General
$60,939
87 transactions
Research
$1,750
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Global Blood Therapeutics, Inc. | $15,800 | 13 | $0 (2022) |
| Acceleron Pharma, Inc. | $9,480 | 3 | $0 (2020) |
| Chiesi USA, Inc. | $8,501 | 8 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $7,597 | 15 | $0 (2024) |
| Octapharma USA, Inc. | $6,925 | 12 | $0 (2018) |
| Agios Pharmaceuticals, Inc. | $5,507 | 1 | $0 (2023) |
| APO-PHARMA INC. | $3,000 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $2,714 | 13 | $0 (2024) |
| Celgene Corporation | $1,902 | 1 | $0 (2021) |
| Horizon Pharma plc | $350.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $268.82 | 7 | Alexion Pharmaceuticals, Inc. ($133.10) |
| 2023 | $14,192 | 12 | Chiesi USA, Inc. ($8,501) |
| 2022 | $4,633 | 9 | Global Blood Therapeutics, Inc. ($4,230) |
| 2021 | $13,456 | 9 | Global Blood Therapeutics, Inc. ($8,695) |
| 2020 | $12,560 | 11 | Acceleron Pharma, Inc. ($9,480) |
| 2019 | $6,489 | 18 | Alexion Pharmaceuticals, Inc. ($6,092) |
| 2018 | $3,788 | 10 | Octapharma USA, Inc. ($3,724) |
| 2017 | $7,302 | 12 | Octapharma USA, Inc. ($3,201) |
All Payment Transactions
88 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/18/2024 | VERTEX PHARMACEUTICALS INCORPORATED | CASGEVY (Biological) | Food and Beverage | In-kind items and services | $29.75 | General |
| Category: SICKLE CELL DISEASE/BETA THALESSEMIA | ||||||
| 09/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $26.27 | General |
| Category: IMMUNOLOGY | ||||||
| 04/17/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $102.13 | General |
| Category: Rare Disease | ||||||
| 03/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: IMMUNOLOGY | ||||||
| 03/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $30.97 | General |
| Category: Rare Disease | ||||||
| 01/30/2024 | Novartis Pharmaceuticals Corporation | VIJOICE (Drug) | Food and Beverage | In-kind items and services | $29.60 | General |
| Category: Oncology | ||||||
| 01/11/2024 | VERTEX PHARMACEUTICALS INCORPORATED | CASGEVY (Biological) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: SICKLE CELL DISEASE/BETA THALESSEMIA | ||||||
| 09/27/2023 | Pierre Fabre Pharmaceuticals, Inc. | HEMANGEOL (Drug) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: PEDIATRIC DERMATOLOGY | ||||||
| 08/23/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $5,506.59 | General |
| Category: Genetically Defined Disease | ||||||
| 04/26/2023 | Terumo BCT, Inc. | Spectra Optia (Device) | Food and Beverage | Cash or cash equivalent | $137.45 | General |
| Category: Therapeutic apheresis and cell collection | ||||||
| 02/25/2023 | Bio Products Laboratory USA, Inc. | Gammaplex (Drug), Coagadex | Food and Beverage | Cash or cash equivalent | $22.89 | General |
| Category: IVIG | ||||||
| 01/29/2023 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $7,500.00 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 01/29/2023 | Chiesi USA, Inc. | FERRIPROX (Drug) | Travel and Lodging | Cash or cash equivalent | $449.20 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 01/29/2023 | Chiesi USA, Inc. | FERRIPROX (Drug) | Food and Beverage | Cash or cash equivalent | $156.97 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 01/29/2023 | Chiesi USA, Inc. | FERRIPROX (Drug) | Travel and Lodging | Cash or cash equivalent | $45.80 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 01/29/2023 | Chiesi USA, Inc. | FERRIPROX (Drug) | Food and Beverage | Cash or cash equivalent | $9.76 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 01/28/2023 | Chiesi USA, Inc. | FERRIPROX (Drug) | Travel and Lodging | Cash or cash equivalent | $213.57 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 01/28/2023 | Chiesi USA, Inc. | FERRIPROX (Drug) | Food and Beverage | Cash or cash equivalent | $101.48 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 01/28/2023 | Chiesi USA, Inc. | FERRIPROX (Drug) | Travel and Lodging | Cash or cash equivalent | $24.00 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 12/20/2022 | Pierre Fabre Pharmaceuticals, Inc. | HEMANGEOL (Drug) | Food and Beverage | In-kind items and services | $35.83 | General |
| Category: PEDIATRIC DERMATOLOGY | ||||||
| 12/10/2022 | Spark Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $106.35 | General |
| 12/09/2022 | Vertex Pharmaceuticals Incorporated | — | Food and Beverage | In-kind items and services | $39.79 | General |
| 09/28/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Honoraria | Cash or cash equivalent | $235.00 | General |
| Category: Sickle Cell Disease | ||||||
| 05/09/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Honoraria | Cash or cash equivalent | $940.00 | General |
| Category: Sickle Cell Disease | ||||||
| 03/15/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Honoraria | Cash or cash equivalent | $940.00 | General |
| Category: Sickle Cell Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Atypcial Hemolytic-Uremic Syndrome aHUS Registry | Alexion Pharmaceuticals, Inc. | $1,750 | 1 |
About Dr. Geetha Puthenveetil, M.D
Dr. Geetha Puthenveetil, M.D is a Pediatric Hematology-Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174626683.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Geetha Puthenveetil, M.D has received a total of $62,689 in payments from pharmaceutical and medical device companies, with $268.82 received in 2024. These payments were reported across 88 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($39,239).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Los Angeles, CA
- Active Since 09/07/2006
- Last Updated 07/09/2007
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1174626683
Products in Payments
- OXBRYTA (Drug) $10,865
- Reblozyl (Drug) $9,480
- FERRIPROX (Drug) $8,501
- SOLIRIS (Drug) $5,792
- PYRUKYND (Drug) $5,507
- WILATE (Biological) $3,724
- NUWIQ (Biological) $3,201
- FERRIPROX 500 MG/1 TABLET (Drug) $3,000
- REBLOZYL (Biological) $1,902
- Ultomiris (Drug) $1,172
- CRIZANLIZUMAB (Biological) $666.00
- ACTIMMUNE (Drug) $350.00
- Soliris (Drug) $300.00
- Spectra Optia (Device) $137.45
- ULTOMIRIS (Biological) $133.10
- JADENU (Drug) $107.61
- Spectra Optia Apheresis System (Device) $103.02
- HEMANGEOL (Drug) $80.97
- PROMACTA (Drug) $65.21
- CASGEVY (Biological) $57.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Los Angeles
Jan Van Tornout, Md, MD
Pediatric Hematology-Oncology — Payments: $470,897
Pediatric Hematology-Oncology $470,897
Noah Federman, M.d, M.D
Pediatric Hematology-Oncology — Payments: $353,544
Pediatric Hematology-Oncology $353,544
Thomas Coates, Md, MD
Pediatric Hematology-Oncology — Payments: $158,777
Pediatric Hematology-Oncology $158,777
Dr. Andrew Dietz, Md, Ms, MD, MS
Pediatric Hematology-Oncology — Payments: $88,475
Pediatric Hematology-Oncology $88,475
Mr. Paul Gaynon, M.d, M.D
Pediatric Hematology-Oncology — Payments: $65,183
Pediatric Hematology-Oncology $65,183
Edward Gomperts, Md, MD
Pediatric Hematology-Oncology — Payments: $65,090
Pediatric Hematology-Oncology $65,090